Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela).

ABSTRACT:

Objectives

To conduct a specialist-led disproportionality analysis of musculoskeletal adverse event reports (MSAERs) in dogs treated with bedinvetmab (Librela™) compared to six comparator drugs with the same indication. Furthermore, to report the findings from a subset of dogs whose adverse event (AE) data underwent independent adjudication by an expert panel.

Study design

Case-control study and case series analysis.

Sample population

The European Medicines Agency's EudraVigilance database (2004-2024) and 19 client-owned dogs.

Methods

An EBVS^® Veterinary Specialist in Surgery individually reviewed all MSAERs to Librela™, Rimadyl^®, Metacam^®, Previcox^®, Onsior^®, Galliprant^®, and Daxocox^®

SUBMITTER: Farrell M 

PROVIDER: S-EPMC12100767 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature